CorMedix Inc

Research CorMedix Inc (CRMD) on Bullrun: valuation model: 221.4% undervalued, market cap USD 599.37M, P/E 3.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCRMD
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal221.4% undervalued
• Market capUSD 599.37M
• P/E3.6
• Financial periodFY2025
• RevenueUSD 311.71M
• Revenue growth617.0%
• Net incomeUSD 163.06M
• Free cash flowUSD 172.79M
• Gross margin88.5%

Valuation Snapshot

Bullrun's latest valuation model marks CorMedix Inc as 221.4% undervalued; latest market cap is USD 599.37M; P/E is 3.6.

About CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.

Frequently asked questions

Is CorMedix Inc overvalued or undervalued?

Bullrun's valuation model currently marks CorMedix Inc as 221.4% undervalued.

What is CorMedix Inc's market cap?

CorMedix Inc's market capitalization is USD 599.37M.

What is CorMedix Inc's P/E ratio?

CorMedix Inc's price-to-earnings (P/E) ratio is 3.6.

What does CorMedix Inc do?

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.